Question 1

What has TB-500 actually been compared with?

Accepted Answer

Four comparisons involving thymosin β4 run through this page, and none was built for the question people arrive with. One set the protein against a placebo in heart-attack patients. One set a combination against each agent alone in a dry eye model. A third ran a thymosin β4 peptide against four unrelated peptides in fish larvae, and a fourth pooled it with two sibling peptides in the brains of mice. Four species, four endpoints, four purposes. None used the fragment sold as TB-500, and none placed one compound above another. A 2026 scoping review searched exactly there, covering six compounds against bone, fracture, muscle, tendon, ligament, meniscus, and cartilage. Overall, 67% of identified publications utilized preclinical animal models, and human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. A literature of that shape contains no ranking, and anything presented as one was assembled rather than measured.

Question 2

Is TB-500 better than BPC-157?

Accepted Answer

Nothing among the research behind this page puts the two in order, and a page supplying a winner would be inventing one. The reviews covering both compounds decline to score either. A 2026 scoping review reports that human data were heterogeneous and revealed modest improvements at best for metabolic bone health and degenerative knee pain. Its conclusion is written across the whole set at once: the claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials. The one report that gave both compounds to the same people is a chart review at a single clinic, where the other 4 patients received a combination of 2 peptide injections of BPC 157 and TB4. A share drawn from four people, telephoned months afterwards, describes those four rather than a difference between compounds. What the published work holds about the pair together is set out on the BPC-157 comparison page.

Question 3

What sits on TB-500's side of a comparison?

Accepted Answer

Almost all of it belongs to the full protein rather than to the piece sold in a vial. A 2026 sports medicine review files the two as separate entries, naming one Tβ4 (thymosin beta-4), and the other TB-500 (thymosin beta-4 fragment). The results carried across that gap were measured on the protein. A 2016 review reports that Tβ4 increases the rate of dermal healing in various preclinical animal models, including diabetic and aged animals, and is active for burns as well. A 2012 review states the mechanism attributed to it: Thymosin β(4) binds to actin and promotes cell migration. So one half of any comparison a reader wants is a fragment carrying a single registered study, and the other half is a protein carrying decades of work. Findings travelling under the shorter name were produced with the longer molecule rather than with the fragment itself.

Question 4

Has the fragment ever been tested against thymosin β4 itself?

Accepted Answer

In these sources, no published experiment has run the fragment and the protein as separate arms, and that is the comparison this compound needs most. The registry keeps the two apart. One is titled TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD, listed as recruiting, with no results posted. Beside it sit two completed entries, A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers and a Phase 1b study of identical design, both of which administered the whole molecule. A genuine test would administer both forms to the same animals, at matched amounts, and read one endpoint on each. No study among the research behind this page has published it, so the argument runs backwards instead: the fragment is assumed to inherit the protein's results because it was cut out of the protein. Every finding below belongs to the molecule actually administered rather than to the one named on a label.

Question 5

What did the one placebo-controlled comparison in people find?

Accepted Answer

This is the only published occasion on which the molecule was measured against anything in a controlled human design, and the result points two ways at once. In a randomized, placebo-controlled, double-blind trial involving 96 STEMI patients, the infarcted areas were significantly reduced in the rhTB4 group, which received the first dose of rhTB4 within 8 h after PCI (n = 43), as compared to the placebo group. STEMI is a major heart attack, PCI reopens the blocked artery, and rhTB4 is the recombinant protein. Then comes the next sentence of the same report. However, the overall differences in infarcted areas were not significantly between the rhTB4 group and the placebo group (n = 96). An early-dosed subgroup separated from placebo while the whole trial did not, and a subgroup identified afterwards is a weaker reading than the trial around it. Its own authors write that further rigorous randomized studies are needed to assess the significance of early rhTB4 use post-myocardial infarction reperfusion.

Question 6

Has thymosin β4 been compared with and without a partner?

Accepted Answer

Once, in a dry eye experiment, and it is the only published comparison of a thymosin β4 combination against the same agents used singly. A 2025 study reported that co-treatment with mesenchymal stem cells (MSCs) and thymosin beta-4 (Tβ4) yielded the best therapeutic outcome against dry eye, surpassing monotherapy outcomes. Monotherapy there means either agent given alone, read in a rodent model of dry eye. Imaging in that animal model revealed increased glutamine levels in cornea following MSC + Tβ4 combined therapy, and inhibition of glutamine reversed the anti-inflammatory, anti-apoptotic, and homeostasis-preserving effects observed with combined therapy. So the two did not simply add up. One partner altered the chemistry of the tissue the other worked in, and a single block in that chain undid the gain. A result of that shape says little about two peptides mixed in a vial. The partner was living cells, the endpoint was inflammation, and the eye belonged to a rodent.

Question 7

How did a thymosin β4 peptide do against four other peptides?

Accepted Answer

One experiment set a peptide built from thymosin β4 beside four unrelated ones and treated all five identically. It ran in fish, and the piece under test was not the one sold as TB-500. A 2025 study synthesised five short peptides and gave each one separately. The selection of peptides was made based on their precursor proteins, which are fatty acid binding protein 7, mitochondrial ribosomal protein S36, MARCKS-related protein 1-B, excitatory amino acid transporter 2 and thymosin beta-4. Behavioral assay using a 6-OHDA zebrafish larvae model suggest that all peptides help in the recovery of motor function with 24 h treatment at two concentrations. Three peptides showed a complete recovery from the 6-OHDA-induced motor impairment, and the report does not say which three. So the nearest thing to a head-to-head test in this family named no winner. A fish larva swimming again within a day and a person with a torn tendon are different questions.

Question 8

How does it compare with thymosin β10 and NP24?

Accepted Answer

Its two closest relatives have been studied alongside it rather than against it. A 2024 study removed a small gland from the brains of young mice and then examined what that gland secretes. In those mice, unbiased peptidomic analysis revealed enrichment of three SCO-derived peptides, namely, thymosin beta 4, thymosin beta 10 and NP24, and their reintroduction into SCO-ablated brain ventricles substantially rescued developmental defects. SCO is the gland they removed, and all three peptides went back in at once. So no part of that repair can be assigned to any one of them. A 2007 review of the family blurs the same line at the level of the molecule. Overexpression or addition of exogenous Tbeta-4 or its homolog, Tbeta-10, alters the actin cytoskeleton, the scaffold a cell builds in order to move. Even the closest comparison available was run as a mixture rather than as a contest.

Question 9

Where does it sit against the agents already in use?

Accepted Answer

One review places thymosin β4 beside the agents already in use for a job it might do. The setting is the airway in cystic fibrosis, where secretions consist of inflammatory-cell derived DNA and filamentous actin polymers, which is similar to pus. That review groups it with an approved option and sets both against a failed one. DNA-active medications such as dornase alfa (Pulmozyme) and potentially actin-depolymerizing drugs such as thymosin beta(4) may be of value in helping to break down airway pus. By contrast, mucolytics that depolymerize mucin, such as N-acetylcysteine, have no proven benefit and carry a risk of epithelial damage. Read the verb. May be of value is how a reviewer writes about a candidate, and it was written in 2007 beside an approved option that had already been through its trials. Being listed next to something established is not the same as being measured against it.

Question 10

How does the evidence compare across tissues?

Accepted Answer

The record is uneven across organs. Heart tissue holds the most: a randomised trial in 96 heart-attack patients, alongside mouse work in which 7-day rhTB4 treatment prevented cardiac dysfunction and fibrosis 28 days post-I/R surgery. Skin comes next. A 2016 review reports that Tβ4 also accelerated the rate of repair in phase 2 trials with patients having pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds, a rare inherited blistering condition. The same review opens by stating that no agent has been identified that significantly accelerates the repair of chronic dermal wounds in humans, the baseline those trials sit against. Tendon and muscle, the tissues the market is built on, hold the least. A 2026 scoping review searched exactly there and found that human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous study designs. So the organ with the best evidence is the one almost nobody buys this compound for.

Question 11

What happened when one study compared two kinds of wound?

Accepted Answer

One small human report carries a comparison inside itself. Nine patients (ages 37-84) with chronic nonhealing neurotrophic corneal epithelial defects were treated with thymosin beta 4 (Tbeta4) sterile eye drops for 28 or 49 days. Those are long-standing wounds on the surface of the eye. The outcome split along the kind of damage. Those with geographic defects (six patients) showed dramatic healing without clinically significant neovascularization, meaning no new vessels grew across the eye. Three patients with punctate epithelial defects did not have a demonstrable change in their clinical findings. Two kinds of wound, one compound, opposite outcomes. The authors call these compassionate use cases, so the drops were given outside a trial because nothing else had worked. There was no control group, so what separates the two sets of patients could be the wound, the dosing window, or chance. Reading the better half of that split alone is how a nine-person series becomes a claim about a compound.

Question 12

How does it compare with the other peptides sold for recovery?

Accepted Answer

It is surveyed with them rather than against them, and both reviews doing the surveying refuse to put the compounds in order. A 2026 scoping review covers 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]). A 2026 sports medicine review runs a longer list ending with Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). The differences they report concern documentation rather than effect. One found that significant heterogeneity existed in dosing and route of administration, which describes disorder in the literature instead of a gap between compounds. The other names something no comparison can hold steady. That review treats the placebo effect as a mediator of peptide efficacy and describes social media amplifying it. It also sets the category inside a parallel "gray market" of unapproved compounds. Appearing in the same table reflects what people ask about together rather than a measured difference between one compound and the next. The scoping review's own conclusion applies to every name on its list: peptide supplements should not currently be recommended as a replacement or adjunct for existing orthopaedic standard of care.

Question 13

Why do comparisons so often measure thymosin β4 rather than give it?

Accepted Answer

Search for comparisons and most of what comes back measures the protein instead of giving it. A 2026 study of melanoma lists thymosin beta-4 among the proteins secreted in significantly higher amounts by resistant cells (compared to the control group). In a 2025 study of brain tissue grown from stem cells, the expression level of the gene TMSB4X that encodes thymosin beta 4 significantly decreased in AD patients' excitatory neurons, AD being Alzheimer disease. In both the protein is the quantity counted, in cells or tissue never given any of it. More or less thymosin β4 in a tissue is a fact about that tissue rather than a result about injecting a fragment of it, and conflating the two is the commonest misreading in this literature.

Question 14

How do the trial and regulatory records compare?

Accepted Answer

The protein and the fragment carry very different paper trails. The registry holds A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers and a Phase 1b study of the same shape, both completed. Two further entries administered the protein to patients with acute myocardial infarction, meaning a heart attack, and both are completed as well. A newer cardiac entry has not started, and an earlier intravenous safety study in volunteers was withdrawn before anyone enrolled. Against all of that, the fragment has one line of its own, still recruiting, measuring blood markers rather than recovery from an injury. Neither form is approved by any regulator. The FDA's recall records hold Thymosin Beta-4 (TB4) for Injection, 15mg, all presentations, and a combined BPC-157/Thymosin Beta-4 for Injection, both withdrawn in 2025 for Lack of Assurance of Sterility. That compares manufacturing records rather than compounds, and it is the only official document in which the two names stand side by side.

TB-500 comparisons and stacks